NEK2 Induces Drug Resistance Mainly through Activation of Efflux Drug Pumps and Is Associated with Poor Prognosis in Myeloma and Other Cancers

Cancer Cell

Volumn 23, Issue 1, 2013, Pages 48-62

  Zhou, Wen ^a,c   Yang, Ye ^a,c   Xia, Jiliang ^a,c   Wang, He ^a,c   Salama, Mohamed E ^b   Xiong, Wei ^c   Xu, Hongwei ^a,c   Shetty, Shashirekha ^d   Chen, Tiehua ^c   Zeng, Zhaoyang ^c   Shi, Lei ^c   Zangari, Maurizio ^c   Miles, Rodney ^b   Bearss, David ^e   Tricot, Guido ^a   Zhan, Fenghuang ^a,c  

^a UNIVERSITY OF IOWA   (United States)

^b ARUP LABORATORIES   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e BRIGHAM YOUNG UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEK2 PROTEIN; PROTEIN KINASE; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CELL PROLIFERATION; CHROMOSOMAL INSTABILITY; DRUG RESISTANCE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HUMAN; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN TARGETING;

EID: 84872373803     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2012.12.001     Document Type: Article

References (49)

1. Avet-Loiseau H., Facon T., Grosbois B., Magrangeas F., Rapp M.J., Harousseau J.L., Minvielle S., Bataille R. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood 2002, 99:2185-2191. Intergroupe Francophone du Myélome.
2. Bahmanyar S., Kaplan D.D., Deluca J.G., Giddings T.H., O'Toole E.T., Winey M., Salmon E.D., Casey P.J., Nelson W.J., Barth A.I. beta-Catenin is a Nek2 substrate involved in centrosome separation. Genes Dev. 2008, 22:91-105.
3. Barlogie B., Tricot G., Anaissie E., Shaughnessy J., Rasmussen E., van Rhee F., Fassas A., Zangari M., Hollmig K., Pineda-Roman M., et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N. Engl. J. Med. 2006, 354:1021-1030.
4. Bergsagel P.L., Kuehl W.M., Zhan F., Sawyer J., Barlogie B., Shaughnessy J. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 2005, 106:296-303.
5. Bienz M. The subcellular destinations of APC proteins. Nat. Rev. Mol. Cell Biol. 2002, 3:328-338.
6. Brunet A., Bonni A., Zigmond M.J., Lin M.Z., Juo P., Hu L.S., Anderson M.J., Arden K.C., Blenis J., Greenberg M.E. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999, 96:857-868.
7. Calasanz M.J., Cigudosa J.C., Odero M.D., Ferreira C., Ardanaz M.T., Fraile A., Carrasco J.L., Solé F., Cuesta B., Gullón A. Cytogenetic analysis of 280 patients with multiple myeloma and related disorders: primary breakpoints and clinical correlations. Genes Chromosomes Cancer 1997, 18:84-93.
8. Carter S.L., Eklund A.C., Kohane I.S., Harris L.N., Szallasi Z. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat. Genet. 2006, 38:1043-1048.
9. Choi C.H. ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell Int. 2005, 5:30.
10. Dan H.C., Cooper M.J., Cogswell P.C., Duncan J.A., Ting J.P.Y., Baldwin A.S. Akt-dependent regulation of NF-kappaB is controlled by mTOR and Raptor in association with IKK. Genes Dev. 2008, 22:1490-1500.
11. Datta S.R., Dudek H., Tao X., Masters S., Fu H., Gotoh Y., Greenberg M.E. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997, 91:231-241.
12. Faragher A.J., Fry A.M. Nek2A kinase stimulates centrosome disjunction and is required for formation of bipolar mitotic spindles. Mol. Biol. Cell 2003, 14:2876-2889.
13. Fodde R., Tomlinson I. Nuclear beta-catenin expression and Wnt signalling: in defence of the dogma. J. Pathol. 2010, 221:239-241.
14. Fridlyand J., Snijders A., Pinkel D., Albertson D., Jain A. Application of Hidden Markov Models to the analysis of the array CGH data. J. Multivariate Anal. 2004, 90:132-153.
15. Fry A.M., Mayor T., Meraldi P., Stierhof Y.D., Tanaka K., Nigg E.A. C-Nap1, a novel centrosomal coiled-coil protein and candidate substrate of the cell cycle-regulated protein kinase Nek2. J. Cell Biol. 1998, 141:1563-1574.
16. Fu G., Ding X., Yuan K., Aikhionbare F., Yao J., Cai X., Jiang K., Yao X. Phosphorylation of human Sgo1 by NEK2A is essential for chromosome congression in mitosis. Cell Res. 2007, 17:608-618.
17. Gardai S.J., Hildeman D.A., Frankel S.K., Whitlock B.B., Frasch S.C., Borregaard N., Marrack P., Bratton D.L., Henson P.M. Phosphorylation of Bax Ser184 by Akt regulates its activity and apoptosis in neutrophils. J. Biol. Chem. 2004, 279:21085-21095.
18. Gehrke I., Gandhirajan R.K., Kreuzer K.A. Targeting the WNT/beta-catenin/TCF/LEF1 axis in solid and haematological cancers: Multiplicity of therapeutic options. Eur. J. Cancer 2009, 45:2759-2767.
19. Hayward D.G., Fry A.M. Nek2 kinase in chromosome instability and cancer. Cancer Lett. 2006, 237:155-166.
20. Helps N.R., Luo X., Barker H.M., Cohen P.T. NIMA-related kinase 2 (Nek2), a cell-cycle-regulated protein kinase localized to centrosomes, is complexed to protein phosphatase 1. Biochem. J. 2000, 349:509-518.
21. Hose D., Rème T., Hielscher T., Moreaux J., Messner T., Seckinger A., Benner A., Shaughnessy J.D., Barlogie B., Zhou Y., et al. Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma. Haematologica 2011, 96:87-95.
22. Huang Z. Bcl-2 family proteins as targets for anticancer drug design. Oncogene 2000, 19:6627-6631.
23. Iida S., Ueda R. Multistep tumorigenesis of multiple myeloma: its molecular delineation. Int. J. Hematol. 2003, 77:207-212.
24. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J. Clin. 2009, 59:225-249.
25. Kops G.J., Weaver B.A., Cleveland D.W. On the road to cancer: aneuploidy and the mitotic checkpoint. Nat. Rev. Cancer 2005, 5:773-785.
26. Kuo M.T., Liu Z., Wei Y., Lin-Lee Y.C., Tatebe S., Mills G.B., Unate H. Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-kappaB signaling. Oncogene 2002, 21:1945-1954.
27. Kwon Y.G., Lee S.Y., Choi Y., Greengard P., Nairn A.C. Cell cycle-dependent phosphorylation of mammalian protein phosphatase 1 by cdc2 kinase. Proc. Natl. Acad. Sci. USA 1997, 94:2168-2173.
28. Kyle R.A., Rajkumar S.V. Monoclonal gammopathy of undetermined significance. Br. J. Haematol. 2006, 134:573-589.
29. Lee E.A., Keutmann M.K., Dowling M.L., Harris E., Chan G., Kao G.D. Inactivation of the mitotic checkpoint as a determinant of the efficacy of microtubule-targeted drugs in killing human cancer cells. Mol. Cancer Ther. 2004, 3:661-669.
30. Misra S., Ghatak S., Toole B.P. Regulation of MDR1 expression and drug resistance by a positive feedback loop involving hyaluronan, phosphoinositide 3-kinase, and ErbB2. J. Biol. Chem. 2005, 280:20310-20315.
31. Monick M.M., Carter A.B., Robeff P.K., Flaherty D.M., Peterson M.W., Hunninghake G.W. Lipopolysaccharide activates Akt in human alveolar macrophages resulting in nuclear accumulation and transcriptional activity of beta-catenin. J. Immunol. 2001, 166:4713-4720.
32. Moreau P., Facon T., Leleu X., Morineau N., Huyghe P., Harousseau J.L., Bataille R., Avet-Loiseau H. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood 2002, 100:1579-1583. Intergroupe Francophone du Myélome.
33. Morris N.R. Mitotic mutants of Aspergillus nidulans. Genet. Res. 1975, 26:237-254.
34. Nicholson K.M., Anderson N.G. The protein kinase B/Akt signalling pathway in human malignancy. Cell. Signal. 2002, 14:381-395.
35. Oakley B.R., Morris N.R. A mutation in Aspergillus nidulans that blocks the transition from interphase to prophase. J. Cell Biol. 1983, 96:1155-1158.
36. Rusan N.M., Peifer M. Original CIN: reviewing roles for APC in chromosome instability. J. Cell Biol. 2008, 181:719-726.
37. Seshan V., Olshen A. DNAcopy: DNA copy number data analysis. R package version 1.20.0 2010, Bioconductor, Seattle, WA.
38. Shannon K.B., Canman J.C., Salmon E.D. Mad2 and BubR1 function in a single checkpoint pathway that responds to a loss of tension. Mol. Biol. Cell 2002, 13:3706-3719.
39. Shaughnessy J.D., Zhan F., Burington B.E., Huang Y., Colla S., Hanamura I., Stewart J.P., Kordsmeier B., Randolph C., Williams D.R., et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007, 109:2276-2284.
40. Shipp M.A., Ross K.N., Tamayo P., Weng A.P., Kutok J.L., Aguiar R.C., Gaasenbeek M., Angelo M., Reich M., Pinkus G.S., et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat. Med. 2002, 8:68-74.
41. Smith M., Marioni J., Hardcastle T., Thorne N. snapCGH: Segmentation, Normalization and Processing of aCGH Data Users' Guide. Bioinformatics 2009, 22:1144-1146.
42. Sonn S., Jeong Y., Rhee K. Nip2/centrobin may be a substrate of Nek2 that is required for proper spindle assembly during mitosis in early mouse embryos. Mol. Reprod. Dev. 2009, 76:587-592.
43. Storchova Z., Kuffer C. The consequences of tetraploidy and aneuploidy. J. Cell Sci. 2008, 121:3859-3866.
44. Wu L., Osmani S.A., Mirabito P.M. A role for NIMA in the nuclear localization of cyclin B in Aspergillus nidulans. J. Cell Biol. 1998, 141:1575-1587.
45. Xiao L., Gong L.L., Yuan D., Deng M., Zeng X.M., Chen L.L., Zhang L., Yan Q., Liu J.P., Hu X.H., et al. Protein phosphatase-1 regulates Akt1 signal transduction pathway to control gene expression, cell survival and differentiation. Cell Death Differ. 2010, 17:1448-1462.
46. Xie Y., Xu K., Linn D.E., Yang X., Guo Z., Shimelis H., Nakanishi T., Ross D.D., Chen H., Fazli L., et al. The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells. J. Biol. Chem. 2008, 283:3349-3356.
47. Xiong W., Wu X., Starnes S., Johnson S.K., Haessler J., Wang S., Chen L., Barlogie B., Shaughnessy J.D., Zhan F. An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma. Blood 2008, 112:4235-4246.
48. Yamada T., Takaoka A.S., Naishiro Y., Hayashi R., Maruyama K., Maesawa C., Ochiai A., Hirohashi S. Transactivation of the multidrug resistance 1 gene by T-cell factor 4/beta-catenin complex in early colorectal carcinogenesis. Cancer Res. 2000, 60:4761-4766.
49. Zhan F., Huang Y., Colla S., Stewart J.P., Hanamura I., Gupta S., Epstein J., Yaccoby S., Sawyer J., Burington B., et al. The molecular classification of multiple myeloma. Blood 2006, 108:2020-2028.